Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 2
2011 3
2012 1
2013 7
2014 8
2015 6
2016 5
2017 5
2018 6
2019 5
2020 6
2021 7
2022 9
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Reversing dopaminergic sensitization.
Castrioto A, Carnicella S, Fraix V, Chabardes S, Moro E, Krack P. Castrioto A, et al. Mov Disord. 2017 Dec;32(12):1679-1683. doi: 10.1002/mds.27213. Epub 2017 Nov 18. Mov Disord. 2017. PMID: 29150871 Review. No abstract available.
Emotional manifestations of PD: Neurobiological basis.
Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Castrioto A, et al. Mov Disord. 2016 Aug;31(8):1103-13. doi: 10.1002/mds.26587. Epub 2016 Apr 4. Mov Disord. 2016. PMID: 27041545 Review.
Cerebrospinal fluid biomarkers in Parkinson disease.
Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P. Parnetti L, et al. Among authors: castrioto a. Nat Rev Neurol. 2013 Mar;9(3):131-40. doi: 10.1038/nrneurol.2013.10. Epub 2013 Feb 19. Nat Rev Neurol. 2013. PMID: 23419373 Review.
Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
Béreau M, Fleury V, Bouthour W, Castrioto A, Lhommée E, Krack P. Béreau M, et al. Among authors: castrioto a. Rev Neurol (Paris). 2018 Nov;174(9):653-663. doi: 10.1016/j.neurol.2018.07.005. Epub 2018 Sep 14. Rev Neurol (Paris). 2018. PMID: 30224159 Review.
The pathogenesis of Pisa syndrome in Parkinson's disease.
Castrioto A, Piscicelli C, Pérennou D, Krack P, Debû B. Castrioto A, et al. Mov Disord. 2014 Aug;29(9):1100-7. doi: 10.1002/mds.25925. Epub 2014 Jun 7. Mov Disord. 2014. PMID: 24909134 Review.
Intermediate repeat expansions of TBP and STUB1: Genetic modifier or pure digenic inheritance in spinocerebellar ataxias?
Barbier M, Davoine CS, Petit E, Porché M, Guillot-Noel L, Sayah S, Fauret AL, Neau JP, Guyant-Maréchal L, Deffond D, Tranchant C, Goizet C, Coarelli G, Castrioto A, Klebe S, Ewenczyk C, Heinzmann A, Charles P, Tchikviladzé M, Van Broeckhoven C, Brice A, Durr A. Barbier M, et al. Among authors: castrioto a. Genet Med. 2023 Feb;25(2):100327. doi: 10.1016/j.gim.2022.10.009. Epub 2022 Nov 23. Genet Med. 2023. PMID: 36422518 Free article.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
73 results